SPA
URGN icon

Sherbrooke Park Advisers’s UroGen Pharma URGN Stock Holding History

Sherbrooke Park Advisers’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,747
Closed -$229K – 725
2025
Q2 		$229K Buy
+16,747
New +$161K 0.1% 361
2024
Q4 		– Sell
-28,393
Closed -$361K – 1175
2024
Q3 		$361K Buy
+28,393
New +$421K 0.08% 484

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Sherbrooke Park Advisers's URGN Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of UroGen Pharma (URGN) in Q3 2025, closing a stake of 16,747 shares — an estimated $229K sold.

Sherbrooke Park Advisers first reported a position in URGN in Q3 2024 and held it in 2 quarters. The position peaked at $361K in Q3 2024. 161 funds tracked by Wall St. Rank hold URGN as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining UroGen Pharma position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 16,747 UroGen Pharma shares in Q3 2025, an estimated $229K.
  • Sherbrooke Park Advisers first reported a position in UroGen Pharma in Q3 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's UroGen Pharma position peaked at $361K in Q3 2024.
  • 161 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.